Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys

ABSTRACT: Objective: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. Methods: This nationwide cross-sectional st...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seif Salem Al-Abri, Adil Al-Wahaibi, Hanan Al-Kindi, Padmamohan J Kurup, Ali Al-Maqbali, Zayid Al-Mayahi, Mohammed Hamed Al-Tobi, Salim Habbash Al-Katheri, Sultan Albusaidi, Mahmood Humaid Al-Sukaiti, Ahmed Yar Mohammed Al Balushi, Iyad Omer Abdelgadir, Nawal Al-Shehi, Essam Morkos, Amal Al-Maani, Bader Al-Rawahi, Fatma Alyaquobi, Abdullah Alqayoudhi, Khalid Al-Harthy, Sulien Al-Khalili, Azza Al-Rashdi, Intisar Al-Shukri, Thamra S. Al Ghafri, Fatma Al-Hashmi, Saeed Mussalam Al Jassasi, Nasser Alshaqsi, Nilanjan Mitra, Humaid Suhail Al Aamry, Parag Shah, Hanan Hassan Al Marbouai, Amany Hamed Al Araimi, Ismail Mohammed Kair, Asim Mohammed Al Manji, Ahmed Said Almallak, Fatma Khamis Al Alawi, Vidyanand Vaidya, Muhammad Muqeetullah, Hanan Alrashdi, Saud Said Nassir Al Jamoudi, Asila Alshaqsi, Abdullah Al Sharji, Hamida Al Shukeiri, Badr Al-Abri, Sulaiman Al-Rawahi, Said H. Al-Lamki, Abdulla Al-Manji, Amina Al-Jardani
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Oman SARS-CoV-2 COVID-19 Antibody seroprevalence Herd immunity Prevalence Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/459e5994f6524158ac249f9e19120aaa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:459e5994f6524158ac249f9e19120aaa
record_format	dspace
spelling	oai:doaj.org-article:459e5994f6524158ac249f9e19120aaa2021-11-30T04:14:25ZSeroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys1201-971210.1016/j.ijid.2021.09.062https://doaj.org/article/459e5994f6524158ac249f9e19120aaa2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007700https://doaj.org/toc/1201-9712ABSTRACT: Objective: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. Methods: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. Results: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). Conclusion: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.Seif Salem Al-AbriAdil Al-WahaibiHanan Al-KindiPadmamohan J KurupAli Al-MaqbaliZayid Al-MayahiMohammed Hamed Al-TobiSalim Habbash Al-KatheriSultan AlbusaidiMahmood Humaid Al-SukaitiAhmed Yar Mohammed Al BalushiIyad Omer AbdelgadirNawal Al-ShehiEssam MorkosAmal Al-MaaniBader Al-RawahiFatma AlyaquobiAbdullah AlqayoudhiKhalid Al-HarthySulien Al-KhaliliAzza Al-RashdiIntisar Al-ShukriThamra S. Al GhafriFatma Al-HashmiSaeed Mussalam Al JassasiNasser AlshaqsiNilanjan MitraHumaid Suhail Al AamryParag ShahHanan Hassan Al MarbouaiAmany Hamed Al AraimiIsmail Mohammed KairAsim Mohammed Al ManjiAhmed Said AlmallakFatma Khamis Al AlawiVidyanand VaidyaMuhammad MuqeetullahHanan AlrashdiSaud Said Nassir Al JamoudiAsila AlshaqsiAbdullah Al SharjiHamida Al ShukeiriBadr Al-AbriSulaiman Al-RawahiSaid H. Al-LamkiAbdulla Al-ManjiAmina Al-JardaniElsevierarticleOmanSARS-CoV-2COVID-19Antibody seroprevalenceHerd immunityPrevalenceInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 269-277 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Oman SARS-CoV-2 COVID-19 Antibody seroprevalence Herd immunity Prevalence Infectious and parasitic diseases RC109-216
spellingShingle	Oman SARS-CoV-2 COVID-19 Antibody seroprevalence Herd immunity Prevalence Infectious and parasitic diseases RC109-216 Seif Salem Al-Abri Adil Al-Wahaibi Hanan Al-Kindi Padmamohan J Kurup Ali Al-Maqbali Zayid Al-Mayahi Mohammed Hamed Al-Tobi Salim Habbash Al-Katheri Sultan Albusaidi Mahmood Humaid Al-Sukaiti Ahmed Yar Mohammed Al Balushi Iyad Omer Abdelgadir Nawal Al-Shehi Essam Morkos Amal Al-Maani Bader Al-Rawahi Fatma Alyaquobi Abdullah Alqayoudhi Khalid Al-Harthy Sulien Al-Khalili Azza Al-Rashdi Intisar Al-Shukri Thamra S. Al Ghafri Fatma Al-Hashmi Saeed Mussalam Al Jassasi Nasser Alshaqsi Nilanjan Mitra Humaid Suhail Al Aamry Parag Shah Hanan Hassan Al Marbouai Amany Hamed Al Araimi Ismail Mohammed Kair Asim Mohammed Al Manji Ahmed Said Almallak Fatma Khamis Al Alawi Vidyanand Vaidya Muhammad Muqeetullah Hanan Alrashdi Saud Said Nassir Al Jamoudi Asila Alshaqsi Abdullah Al Sharji Hamida Al Shukeiri Badr Al-Abri Sulaiman Al-Rawahi Said H. Al-Lamki Abdulla Al-Manji Amina Al-Jardani Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
description	ABSTRACT: Objective: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. Methods: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. Results: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). Conclusion: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
format	article
author	Seif Salem Al-Abri Adil Al-Wahaibi Hanan Al-Kindi Padmamohan J Kurup Ali Al-Maqbali Zayid Al-Mayahi Mohammed Hamed Al-Tobi Salim Habbash Al-Katheri Sultan Albusaidi Mahmood Humaid Al-Sukaiti Ahmed Yar Mohammed Al Balushi Iyad Omer Abdelgadir Nawal Al-Shehi Essam Morkos Amal Al-Maani Bader Al-Rawahi Fatma Alyaquobi Abdullah Alqayoudhi Khalid Al-Harthy Sulien Al-Khalili Azza Al-Rashdi Intisar Al-Shukri Thamra S. Al Ghafri Fatma Al-Hashmi Saeed Mussalam Al Jassasi Nasser Alshaqsi Nilanjan Mitra Humaid Suhail Al Aamry Parag Shah Hanan Hassan Al Marbouai Amany Hamed Al Araimi Ismail Mohammed Kair Asim Mohammed Al Manji Ahmed Said Almallak Fatma Khamis Al Alawi Vidyanand Vaidya Muhammad Muqeetullah Hanan Alrashdi Saud Said Nassir Al Jamoudi Asila Alshaqsi Abdullah Al Sharji Hamida Al Shukeiri Badr Al-Abri Sulaiman Al-Rawahi Said H. Al-Lamki Abdulla Al-Manji Amina Al-Jardani
author_facet	Seif Salem Al-Abri Adil Al-Wahaibi Hanan Al-Kindi Padmamohan J Kurup Ali Al-Maqbali Zayid Al-Mayahi Mohammed Hamed Al-Tobi Salim Habbash Al-Katheri Sultan Albusaidi Mahmood Humaid Al-Sukaiti Ahmed Yar Mohammed Al Balushi Iyad Omer Abdelgadir Nawal Al-Shehi Essam Morkos Amal Al-Maani Bader Al-Rawahi Fatma Alyaquobi Abdullah Alqayoudhi Khalid Al-Harthy Sulien Al-Khalili Azza Al-Rashdi Intisar Al-Shukri Thamra S. Al Ghafri Fatma Al-Hashmi Saeed Mussalam Al Jassasi Nasser Alshaqsi Nilanjan Mitra Humaid Suhail Al Aamry Parag Shah Hanan Hassan Al Marbouai Amany Hamed Al Araimi Ismail Mohammed Kair Asim Mohammed Al Manji Ahmed Said Almallak Fatma Khamis Al Alawi Vidyanand Vaidya Muhammad Muqeetullah Hanan Alrashdi Saud Said Nassir Al Jamoudi Asila Alshaqsi Abdullah Al Sharji Hamida Al Shukeiri Badr Al-Abri Sulaiman Al-Rawahi Said H. Al-Lamki Abdulla Al-Manji Amina Al-Jardani
author_sort	Seif Salem Al-Abri
title	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_short	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_full	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_fullStr	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_full_unstemmed	Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_sort	seroprevalence of sars-cov-2 antibodies in the general population of oman: results from four successive nationwide sero-epidemiological surveys
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/459e5994f6524158ac249f9e19120aaa
work_keys_str_mv	AT seifsalemalabri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT adilalwahaibi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT hananalkindi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT padmamohanjkurup seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alialmaqbali seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT zayidalmayahi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT mohammedhamedaltobi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT salimhabbashalkatheri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT sultanalbusaidi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT mahmoodhumaidalsukaiti seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT ahmedyarmohammedalbalushi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT iyadomerabdelgadir seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT nawalalshehi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT essammorkos seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT amalalmaani seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT baderalrawahi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT fatmaalyaquobi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT abdullahalqayoudhi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT khalidalharthy seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT sulienalkhalili seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT azzaalrashdi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT intisaralshukri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT thamrasalghafri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT fatmaalhashmi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT saeedmussalamaljassasi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT nasseralshaqsi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT nilanjanmitra seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT humaidsuhailalaamry seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT paragshah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT hananhassanalmarbouai seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT amanyhamedalaraimi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT ismailmohammedkair seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT asimmohammedalmanji seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT ahmedsaidalmallak seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT fatmakhamisalalawi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT vidyanandvaidya seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT muhammadmuqeetullah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT hananalrashdi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT saudsaidnassiraljamoudi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT asilaalshaqsi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT abdullahalsharji seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT hamidaalshukeiri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT badralabri seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT sulaimanalrawahi seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT saidhallamki seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT abdullaalmanji seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT aminaaljardani seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
_version_	1718406798745010176

Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys

Ejemplares similares